Literature DB >> 9242521

Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions.

C M Eischen1, T J Kottke, L M Martins, G S Basi, J S Tung, W C Earnshaw, P J Leibson, S H Kaufmann.   

Abstract

The Fas/Fas ligand (FasL) pathway is widely involved in apoptotic cell death in lymphoid and nonlymphoid cells. It has recently been postulated that many chemotherapeutic agents also induce cell death by activating the Fas/FasL pathway. In the present study we compared apoptotic pathways induced by anti-Fas or chemotherapeutic agents in the Jurkat human T-cell leukemia line. Immunoblotting showed that treatment of wild-type Jurkat cells with anti-Fas or the topoisomerase II-directed agent etoposide resulted in proteolytic cleavage of precursors for the cysteine-dependent aspartate-directed proteases caspase-3 and caspase-7 and degradation of the caspase substrates poly(ADP-ribose) polymerase (PARP) and lamin B1. Likewise, affinity labeling with N-(N(alpha)-benzyloxycarbonylglutamyl-N(epsilon)-biotinyllysyl+ ++)aspartic acid [(2,6-dimethyl-benzoyl)oxy]methyl ketone [Z-EK(bio)D-amok] labeled the same five active caspase species after each treatment, suggesting that the same downstream apoptotic pathways have been activated by anti-Fas and etoposide. Treatment with ZB4, an antibody that inhibits Fas-mediated cell death, failed to block etoposide-induced apoptosis, raising the possibility that etoposide does not initiate apoptosis through Fas/FasL interactions. To further explore the relationship between Fas- and chemotherapy-induced apoptosis, Fas-resistant Jurkat cells were treated with various chemotherapeutic agents. Multiple independently derived Fas-resistant Jurkat lines underwent apoptosis that was indistinguishable from that of the Fas-sensitive parental cells after treatment with etoposide, doxorubicin, topotecan, cisplatin, methotrexate, staurosporine, or gamma-irradiation. These results indicate that antineoplastic treatments induce apoptosis through a Fas-independent pathway even though Fas- and chemotherapy-induced pathways converge on common downstream apoptotic effector molecules.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242521

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines.

Authors:  M Tolomeo; S Grimaudo; S Milano; M La Rosa; V Ferlazzo; G Di Bella; C Barbera; D Simoni; P D'Agostino; E Cillari
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model.

Authors:  R Liu; C Page; D R Beidler; M S Wicha; G Núñez
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.

Authors:  Xue Wei Meng; Michael P Heldebrant; Karen S Flatten; David A Loegering; Haiming Dai; Paula A Schneider; Timothy S Gomez; Kevin L Peterson; Sergey A Trushin; Allan D Hess; B Douglas Smith; Judith E Karp; Daniel D Billadeau; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2009-11-03       Impact factor: 5.157

4.  Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling. Implications for cancer therapy.

Authors:  K Newton; A Strasser
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

5.  FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS.

Authors:  Erik D Foehr; Gustavo Lorente; Valerie Vincent; Karoly Nikolich; Roman Urfer
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

6.  The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells.

Authors:  Basile Stamatopoulos; Nathalie Meuleman; Cécile De Bruyn; Alain Delforge; Dominique Bron; Laurence Lagneaux
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

7.  Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer.

Authors:  I Meinhold-Heerlein; F Stenner-Liewen; H Liewen; S Kitada; M Krajewska; S Krajewski; J M Zapata; A Monks; D A Scudiero; T Bauknecht; J C Reed
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

8.  Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia.

Authors:  Jun Yang; P K Epling-Burnette; Jeffrey S Painter; Jianxiang Zou; Fanqi Bai; Sheng Wei; Thomas P Loughran
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

9.  Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells.

Authors:  Claudia Friesen; Annelie Lubatschofski; Jörg Kotzerke; Inga Buchmann; Sven N Reske; Klaus-Michael Debatin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-26       Impact factor: 9.236

10.  The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis.

Authors:  M J Smyth; E Krasovskis; V R Sutton; R W Johnstone
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.